Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

408 Index
±, see also cancer
±, see also carcinoma
tuning, evolutionary 206±209
u
underexpressed genes 23
universal tumor antigens 3±16
v
vaccination
±, antitumor 218±221
±, cancer 179±203
±, CpG DNA as an adjuvant 276f.
±, delivery and schedule 187f.
±, hybrid-cell 187, 230±252
±, peptide 234
±, pw-CEA 320
±, RNA 187
±, therapeutic 5
±, virus 234
±, whole-cell 187, 221, 260f.
vaccines
±, cancer 25f.
±, DNA 321±327
±, non-individualized tumor 332
±, preventive cancer 232
±, TAP 77
±, tumor-specific 256ff.
variable heavy chain (V H) 355±358
variable light chain (VL) 355±358
variable region fragment (Fv)
±, immunotoxins 355±362, 366±369
±, T-body approach 287f.
vascular endothelial growth factor (VEGF)
105
±, effects of IL-10 166
vascular leak syndrome (VLS) 367
Vb11 and Vb8 T cell receptor 340
VEGF see vascular endothelial growth factor
vesicular stomatitis virus (VSV), HSPs 254
VH see variable heavy chain
V L see variable light chain
viral antigens 232
viral-gene encoded antigens 22
virus specific peptides, HSPs 255
virus vaccination 234
vitiligo 211, 220
±, HCV 240
VLS see vascular leak syndrome
VSV see vesicular stomatitis virus
w
whole-cell vaccination 221
±, dendritic cells 187
±, HSPs 260f.
x
xenomice see transgenic mice
z
ZAP-70 family, PTKs 289
z chain
±, CD3 102, 288
±, TCR-associated 106